Apogee sold to Blackstone
Apogee Therapeutics agrees to $1.3 billion acquisition by Blackstone, sending shares higher. The deal is expected to expand Blackstone's presence in the biotech sector.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.